Purpose: This Phase II trial evaluated the safety and efficacy of neoadjuvant chemotherapy (NAC) with S-1 and oxaliplatin (SOX) plus bevacizumab (Bev) in patients with colorectal liver metastasis (CRLM). Methods: Patients with initially resectable CRLM received four cycles of SOX plus Bev as NAC. We adopted the R0 resection rate as the primary endpoint, and the threshold R0 resection rate was set at 80%. Results: Between December 2010 and August 2014, 61 patients were enrolled in this study and all started NAC. The completion rate of NAC was 82.0%. Three patients (4.9%) developed severe liver dysfunction caused by NAC and one patient finally decided against resection. Three patients (4.9%) were judged as having progressive disease during or after NAC and did not undergo liver resection. Among 57 patients who underwent liver resection after NAC, three patients were diagnosed with CRLM by pre-treatment imaging modalities and received NAC although a final pathological diagnosis was another malignant disease or benign condition. Finally, 47 of the 54 patients (87.0%) with resected CRLM achieved R0 resection. The pathological complete response rate of the 54 patients was 13.0%, and 31.5% were judged as pathological responders. However, the R0 resection rate of 77.0% in the entire cohort did not meet the endpoint. Conclusions: NAC with SOX plus Bev has an acceptable toxicity profile and achieved a satisfactory pathological response. However, accuracy of pre-operative diagnoses and liver dysfunction caused by NAC were serious problems. Easy introduction of NAC for initially resectable CRLM should not be performed.
Introduction
Use of anticancer drugs during the perioperative period for colorectal liver metastasis (CRLM) has been widespread worldwide without sufficient evidence of their effectiveness and safety. According to the FFCD9002 trial of adjuvant chemotherapy, fluorouracil (FU) and folinic acid improved progression-free survival (PFS) after liver resection compared with surgery alone, although there were no benefits in overall survival (1) . We previously reported that adjuvant S-1 brought about favorable survival with low toxicity for low-risk CRLM (2, 3) . On the other hand, although preoperative induction chemotherapy for initially unresectable or borderline lesions is generally accepted, neoadjuvant chemotherapy (NAC) for easily resectable CRLM has not been fully evaluated and its effectiveness is still doubtful (4). Nasti et al. reported a small Phase II trial of NAC using FOLFIRI plus bevacizumab (Bev) for initially resectable CRLM (5) . In that trial, the R0 rate of 84.6% and pathological complete response (pCR) rate of 14% were favorable. The EORTC 40 983 study, in which the effectiveness of perioperative FOLFOX was assessed, showed improvement in PFS; however, the long-term results failed to show an overall survival benefit (6, 7) . The new EOPC trial, in which the effectiveness of perioperative FOLFOX plus cetuximab was assessed, also failed to show a survival benefit (8) .
It is well known that NAC causes chemotherapy-induced liver injury, including sinusoidal obstructive syndrome (SOS) and steatohepatitis (9) . This might eliminate the opportunity for liver resection or increase post-operative complications especially when it is given for more than 6 months (10). However, many reports showed that preoperative optimal oxaliplatin-based chemotherapy, mainly FOLFOX, for initially marginally resectable or unresectable CRLM was safe and tolerable (6, 8, (11) (12) (13) (14) (15) .
In a palliative setting, a randomized trial showed that SOX, capecitabine plus oxaliplatin (CapOX), and FOLFOX had equivalent toxicity profiles and efficacy (16) (17) (18) . A large Japanese randomized trial showed that S-1 and oxaliplatin (SOX) plus Bev was not inferior to FOLFOX plus Bev with respect to PFS as first-line treatment for metastatic colorectal cancer (16) . A Korean randomized trial also showed that SOX was similar to CapeOX as firstline treatment for metastatic colorectal cancer in an analysis of PFS (17) . Therefore, we conducted this prospective study to confirm the safety and efficacy of neoadjuvant SOX plus Bev in patients with initially resectable CRLM. We adopted the R0 resection rate as the primary endpoint.
Patients and methods

Eligibility criteria
Eligibility criteria for entry into this study were as follows: (1) histologically proven colorectal adenocarcinoma; (2) no detectable extrahepatic metastasis; (3) the primary tumor had to be either already resected (R0 resection) or judged to be resectable (in case of synchronous metastases) by a multidisciplinary team at each hospital; (4) age 20-79 years; (5) Eastern Cooperative Oncology Group performance status of 0-1; (6) no previous chemotherapy or radiotherapy for metastatic disease (including any adjuvant chemotherapy for colorectal primary tumor completed within 3 months before enrollment); (7) adequate gastrointestinal function; and (8) adequate hematologic, liver and renal functions. Patients with a past history of chemotherapy using oxaliplatin, S-1, or Bev were excluded in any situation. In addition, absence of other severe medical conditions was required for study entry. For example, patients who had any of the following conditions were excluded: infection or suspected infection with fever, congestive heart failure, uncontrolled diabetes or hypertension, interstitial pneumonia or lung fibrosis, or liver cirrhosis or active hepatitis. Pregnant women as well as patients with another cancer in the past 5 years were also excluded.
Before enrollment, enhanced chest and abdominopelvic multidetector row computed tomography (MDCT) with a 5 mm or thinner slice thickness was required to identify distant disease in all patients. Gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic response imaging (EOB-MRI) was also required to evaluate resectability. Indocyanine green (ICG) retention rate was tested before enrollment. The type and extent of the preceding liver resection (non-anatomical or anatomical) was decided by the surgeon at the treating hospital. Pre-operative portal embolization was permitted if necessary. Intraoperative ultrasonography was required to identify metastatic lesions in the remnant liver. Oncologic data (time from resection of primary tumor, timing of liver metastasis, location of primary tumor, previous adjuvant chemotherapy for primary lesion, maximum tumor size, number of liver metastases, preoperative carcinoembryonic antigen [CEA] level), operative and post-operative details (operative procedures, operative time, blood loss and post-operative complications) and pathological data were recorded on a specific data sheet.
Written informed consent was obtained from each patient before enrollment. The protocol was approved by the institutional review boards of all participating hospitals.
Eligibility for the study was evaluated in accordance with the classification of the Japanese Society for Cancer of Colon and Rectum (19) , and all patients were additionally staged using the 6th edition of the UICC TNM staging system (20) .
Neoadjuvant chemotherapy
Patients received SOX plus Bev (on Day 1, 7.5 mg/kg intravenous infusion of Bev and 130 mg/m 2 intravenous infusion of oxaliplatin; assigned dose of S-1 twice a day from after dinner on Day 1 to after breakfast on Day 15, followed by a 7-day break) as NAC. Dose of S-1 was decided based on the body surface area (BSA) as follows: BSA < 1.25 m 2 , 40 mg; BSA ≥ 1.25 to <1.50 m 2 , 50 mg;
and BSA ≥ 1.50 m 2 , 60 mg. This regimen was repeated every 3 weeks. Treatment was administered for four cycles, but the fourth cycle of therapy did not include Bev. Bev was omitted in the first cycle in patients with synchronous liver metastasis who had undergone primary resection or colostomy within 4 weeks before administration of chemotherapy. Relative dose intensity (RDI) was calculated as the actual dose intensity divided by the planned dose intensity and multiplied by 100. Adverse events were assessed according to the Common Toxicity Criteria of the National Cancer Institute (version 3.0).
Surgery
Pre-operative reevaluation of the tumor and liver function was the same as the pre-treatment evaluation. MDCT, EOB-MRI and the ICG retention test were required to reevaluate the final resectability.
Objective response was assessed on the basis of the Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1.
Complete response and partial response were regarded as objective responses. Liver resection was basically stipulated to be performed 2-8 weeks after the completion of NAC.
Pathological assessment
Resected specimens were subjected to conventional processing. Grades of histological regression were assessed according to the tumor regression grade (TRG) proposed by Dworak et al. (21) . Patients were divided into two groups according to the regression grade: responders (TRG 3/4) and non-responders (TRG 0-2).
Follow-up
No adjuvant chemotherapy was allowed after R0 resection. For patients with consequent R1-2 resection or non-resection, subsequent therapy was not stipulated and was decided by each clinician. Recurrence was diagnosed based on imaging studies, mainly chest and abdominopelvic computed tomography, which were performed at 3-month intervals during the first 3 years after surgery.
Endpoints and statistical analysis
The primary endpoint was the R0 resection rate in all registered patients. Secondary endpoints were PFS, overall survival, objective and pathological response rate, post-operative complication rate, RDI, and adverse events. Calculation of the sample size was based on an expected R0 resection rate of 91% and a threshold R0 resection rate of 80% using a 2-sided alpha error of 0.10 and a statistical power of 80%. The planned sample size was 60 patients, allowing for a 10% dropout rate. We evaluated the primary endpoint and other short-term outcomes, including the objective and pathological response rate, post-operative complication rate, RDI, and adverse events. Statistical analysis was done using SPSS software version 20.0 (IBM Japan Ltd, Tokyo, Japan).
This trial was registered in the UMIN Clinical Trials Registry (www.umin.ac.jp/ctr/) as 000 004 706.
Results
We enrolled 61 patients (44 males and 17 females; median age 64 years) at 15 participating hospitals between December 2010 and August 2014. All patients were eligible and could start NAC. The baseline characteristics are listed in Table 1 . Twenty-three patients (37.7%) had a solitary CRLM and 12 patients (19.7%) had solitary metachronous disease. Seven patients had 5 or more CRLM. Fortyfive patients (73.8%) had synchronous CRLM, and 30 of the 45 patients (66.7%) had undergone primary resection before administration of NAC. Of the 16 patients with metachronous CRLM, 6 had received adjuvant oral FU after primary resection. Table 2 shows the toxicity profile during this regimen. The most frequent Grade 3 or higher hematologic toxicity involved neutropenia, occurring in 5 of the 61 patients (8.2%). No patient had Grade 3 febrile neutropenia. Other Grade 3 hematologic toxicities were leukopenia in two patients (3.3%) and thrombocytopenia in one patient (1.6%). Non-hematologic toxicities of Grade 3 or higher were diarrhea in 3.3% of patients and anorexia in 1.6% of patients.
Treatment results after NAC are shown in Table 3 . The completion rate of the scheduled four cycles of NAC was 82.0%. The reasons for discontinuation of chemotherapy were adverse events in six patients (9.8%), misgivings about disappearance of the tumor in three patients (4.9%), and progressive disease identified at the interim assessment in two patients (3.3%). Forty-two patients (68.9%) were judged as objective responders, including three patients with a clinical complete response. ICG retention rate at 15 min (ICG-R15, %) after NAC was 30% or greater in three patients (4.9%). Those patients were judged as having severe liver dysfunction and could not undergo liver resection within 8 weeks after completion of NAC. Although 2 of the 3 patients underwent liver resection after recovery of liver function, the third patient finally decided against liver resection (Fig. 1) . Table 4 presents the operative and pathological results. The median time from the last administration of Bev to liver resection was 62 days. Excluding three patients who were judged as having objective progressive disease and one patient with severe liver dysfunction, 57 patients underwent liver resection after NAC. Three patients did not have pathologically confirmed CRLM but were diagnosed as having CRLM by pretreatment imaging modalities and received NAC although the final pathological diagnosis from resected specimens was another malignant disease or a benign condition (Fig. 1) . As a result, 47 of the 54 patients (87.0%) with resected CRLM achieved R0 resection. The pCR rate of the 54 patients was 13.0%, and 31.5% were judged as pathological responders. However, the R0 resection rate in the entire cohort was 77.0%.
Discussion
Our trial only included patients declared to have resectable CRLM by multimodal conferences in each treating hospitals; therefore we set the expected R0 resection rate to be 91%. The R0 resection rate for CRLM was reported to be 83-95%, and the rate tended to increase in accordance with improvements in surgical skills and preoperative diagnosis (22) (23) (24) (25) (26) (27) . The EORTC 40 983 study, which prospectively investigated treatment results for initially resectable CRLM, reported that the operated and resection rates of the patients in the surgery alone group were 93.4% and 83.5%, respectively (6) . NAC might decrease the liver resection rate by negative effects including liver dysfunction and tumor progression during NAC. Therefore we set the threshold R0 resection rate at 80%; however, the result of 77.0% did not meet the primary endpoint. This result urged us not to hastily consider administering NAC for initially resectable CRLM.
In this study, the actual R0 resection rate of 87.0% in patients who received liver resection for CRLM after NAC was satisfactory. Additionally, the pCR rate of 13.0% and good response rate of 31.5% were promising. Although disease progression during NAC was seen in three patients (4.9%), some clinicians consider it as a method to avoid non-essential liver resection. However, this study clarified that liver dysfunction caused by chemotherapeutic drugs 
National Cancer Institute Common Toxicity Criteria, version 3.0., AST, aspartate aminotransferase; ALT, alanine aminoransferase. RECIST, response criteria in solid tumors; ICG, indocyanine green. and an inaccurate pre-operative diagnosis were crucial problems with NAC. Most patients with CRLM have normal liver function, which is highly different from patients who have received liver resection for hepatocellular carcinoma accompanied by hepatitis. It was reported that the use of Bev with cytotoxic drugs avoided liver injury including SOS; therefore, we added Bev in the NAC regimen (28, 29) . Moreover, in this trial, pre-treatment liver function in all enrolled patients was evaluated by the ICG retention test. Several published reports showed the usefulness of the ICG retention test in evaluating impaired liver function after NAC (30) (31) (32) . In our study, although one patient could not tolerate the ICG retention test, ICG-R15 in the other patients was confirmed to be less than 20 and all patients were judged to be operable before enrollment. However, the pre-operative ICG retention test showed that ICG-R15 was 20% or higher in eight patients and 30% or higher in three patients. As a result, three patients could not undergo liver resection within 8 weeks after completion of the NAC, and one patient finally became inoperable. We must appreciate that NAC might impede liver function beyond expectations.
Needless to say, the pre-operative diagnosis of liver tumors is not flawless. Even in this day of advanced diagnostic modalities, some cholangiocarcinomas, hepatocellular carcinomas, and benign regions could possibly be misdiagnosed as CRLM (33, 34) . This indicates that we might offer pointless treatment to patients with another kind of liver tumor. Actually, this trial included three patients (4.9%) without CRLM even though they were assessed by both MDCT with a 5 mm or thinner slice and EOB-MRI. In the (5) . Most of the literature about CRLM describes retrospective studies and most patients were pre-operatively diagnosed as having CRLM, but some patients had been misdiagnosed as having CRLM and received NAC and their data were subsequently excluded from retrospective studies of CRLM. To clarify the safety and effectiveness of NAC for CRLM, we must assess prospective data based on the pretreatment diagnosis.
Limitations of this study are the small sample used, that it was a single-arm study, and that it included several cases of misdiagnosis. Moreover, although eligibility was simply the diagnosis of resectable CRLM, the definition of resectability is a sticky problem. It is generally accepted that definitions of resectable CRLM differ widely among treatment centers and the designation of resectable CRLM brings about different expected R0 resection rates. The EORTC 40 983 study stipulated that resectable CRLM could potentially include 1-4 resectable liver metastases without a detectable extrahepatic tumor (6) . In our trial, 88.5% of the patients met the EORTC 40 983 study criteria; therefore we think that our results were adequate to assess the R0 resection rate for resectable CRLM. Adam et al. reported from a large amount of data of the LiverMetSurvey that NAC does not seem to benefit the outcome in patients with a solitary metachronous CRLM (35) . In this study, 12 of the 61 patients (19.7%) had a solitary metachronous CRLM. Indications for NAC for resectable CRLM must be reconsidered on the basis of such negative data.
In conclusion, NAC with SOX plus Bev has an acceptable toxicity profile and brought about a satisfactory pathological response. However, accuracy of the pre-operative diagnoses and the liver dysfunction caused by NAC were serious problems. This trial suggested that we could not ignore the disadvantages of NAC. Oncologists should keep these facts in mind and indications for NAC should be strictly selected. Easy introduction of NAC for initially resectable CRLM should not be performed.
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